Lirentelimab - CISMeF

Preferred Label : Lirentelimab;

NCIt synonyms : Monoclonal Antibody AK 002;

NCIt definition : A humanized, nonfucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory receptor sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) expressed on human mast cells and eosinophils, with potential anti-inflammatory activity. Upon administration, lirentelimab targets and binds to Siglec-8 expressed on the surface of mast cells and eosinophils. This may inhibit mast cell activation and deplete eosinophils through antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. This may reduce abnormal proliferation of mast cells and eosinophils, which plays a key role in allergic and inflammatory responses.;

UNII : SWS48LJU3T;

CAS number : 2283348-97-8;

Molecule name : AK 002; AK002;

NCI Metathesaurus CUI : CL512560;

Détails

Origin ID

C129591;

UMLS CUI

C5446305;

Currated CISMeF NLP mapping
- Lirentelimab [SMS substance]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- AK002 [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients